nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—Discomfort—Betamethasone—hematologic cancer	0.000234	0.000308	CcSEcCtD
Methysergide—Discomfort—Dexamethasone—hematologic cancer	0.000234	0.000308	CcSEcCtD
Methysergide—Dermatitis—Thalidomide—hematologic cancer	0.000234	0.000308	CcSEcCtD
Methysergide—Dizziness—Alitretinoin—hematologic cancer	0.000234	0.000307	CcSEcCtD
Methysergide—Diarrhoea—Vincristine—hematologic cancer	0.000233	0.000306	CcSEcCtD
Methysergide—Pain—Prednisolone—hematologic cancer	0.000233	0.000306	CcSEcCtD
Methysergide—Asthenia—Gemcitabine—hematologic cancer	0.000232	0.000305	CcSEcCtD
Methysergide—Dizziness—Ifosfamide—hematologic cancer	0.000231	0.000304	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—hematologic cancer	0.000229	0.000301	CcSEcCtD
Methysergide—Nausea—Thiotepa—hematologic cancer	0.000228	0.0003	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000228	0.0003	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—hematologic cancer	0.000228	0.000299	CcSEcCtD
Methysergide—Feeling abnormal—Etoposide—hematologic cancer	0.000227	0.000299	CcSEcCtD
Methysergide—Oedema—Dexamethasone—hematologic cancer	0.000227	0.000299	CcSEcCtD
Methysergide—Oedema—Betamethasone—hematologic cancer	0.000227	0.000299	CcSEcCtD
Methysergide—Diarrhoea—Mitoxantrone—hematologic cancer	0.000227	0.000298	CcSEcCtD
Methysergide—Diarrhoea—Irinotecan—hematologic cancer	0.000227	0.000298	CcSEcCtD
Methysergide—Vomiting—Carmustine—hematologic cancer	0.000227	0.000298	CcSEcCtD
Methysergide—Insomnia—Triamcinolone—hematologic cancer	0.000226	0.000298	CcSEcCtD
Methysergide—Gastrointestinal pain—Etoposide—hematologic cancer	0.000226	0.000297	CcSEcCtD
Methysergide—Dizziness—Vincristine—hematologic cancer	0.000225	0.000296	CcSEcCtD
Methysergide—Rash—Carmustine—hematologic cancer	0.000225	0.000296	CcSEcCtD
Methysergide—Ill-defined disorder—Prednisone—hematologic cancer	0.000225	0.000296	CcSEcCtD
Methysergide—Dermatitis—Carmustine—hematologic cancer	0.000225	0.000295	CcSEcCtD
Methysergide—Vomiting—Alitretinoin—hematologic cancer	0.000225	0.000295	CcSEcCtD
Methysergide—Paraesthesia—Triamcinolone—hematologic cancer	0.000225	0.000295	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—hematologic cancer	0.000224	0.000295	CcSEcCtD
Methysergide—Feeling abnormal—Prednisolone—hematologic cancer	0.000224	0.000295	CcSEcCtD
Methysergide—Dyspnoea—Triamcinolone—hematologic cancer	0.000223	0.000293	CcSEcCtD
Methysergide—Rash—Alitretinoin—hematologic cancer	0.000223	0.000293	CcSEcCtD
Methysergide—Dermatitis—Alitretinoin—hematologic cancer	0.000223	0.000293	CcSEcCtD
Methysergide—Thrombocytopenia—Dexamethasone—hematologic cancer	0.000222	0.000292	CcSEcCtD
Methysergide—Thrombocytopenia—Betamethasone—hematologic cancer	0.000222	0.000292	CcSEcCtD
Methysergide—Vomiting—Ifosfamide—hematologic cancer	0.000222	0.000292	CcSEcCtD
Methysergide—Tachycardia—Dexamethasone—hematologic cancer	0.000222	0.000291	CcSEcCtD
Methysergide—Tachycardia—Betamethasone—hematologic cancer	0.000222	0.000291	CcSEcCtD
Methysergide—Diarrhoea—Gemcitabine—hematologic cancer	0.000221	0.000291	CcSEcCtD
Methysergide—Nausea—Thalidomide—hematologic cancer	0.000221	0.00029	CcSEcCtD
Methysergide—Dyspepsia—Triamcinolone—hematologic cancer	0.00022	0.00029	CcSEcCtD
Methysergide—Rash—Ifosfamide—hematologic cancer	0.00022	0.00029	CcSEcCtD
Methysergide—Dermatitis—Ifosfamide—hematologic cancer	0.00022	0.000289	CcSEcCtD
Methysergide—Dizziness—Irinotecan—hematologic cancer	0.000219	0.000288	CcSEcCtD
Methysergide—Malaise—Prednisone—hematologic cancer	0.000219	0.000287	CcSEcCtD
Methysergide—Body temperature increased—Etoposide—hematologic cancer	0.000218	0.000287	CcSEcCtD
Methysergide—Abdominal pain—Etoposide—hematologic cancer	0.000218	0.000287	CcSEcCtD
Methysergide—Vomiting—Vincristine—hematologic cancer	0.000217	0.000285	CcSEcCtD
Methysergide—Asthenia—Cisplatin—hematologic cancer	0.000216	0.000284	CcSEcCtD
Methysergide—Fatigue—Triamcinolone—hematologic cancer	0.000216	0.000284	CcSEcCtD
Methysergide—Rash—Vincristine—hematologic cancer	0.000215	0.000282	CcSEcCtD
Methysergide—Dermatitis—Vincristine—hematologic cancer	0.000215	0.000282	CcSEcCtD
Methysergide—Oedema peripheral—Epirubicin—hematologic cancer	0.000214	0.000282	CcSEcCtD
Methysergide—Pain—Triamcinolone—hematologic cancer	0.000214	0.000281	CcSEcCtD
Methysergide—Nausea—Carmustine—hematologic cancer	0.000212	0.000279	CcSEcCtD
Methysergide—Vomiting—Irinotecan—hematologic cancer	0.000211	0.000277	CcSEcCtD
Methysergide—Vomiting—Mitoxantrone—hematologic cancer	0.000211	0.000277	CcSEcCtD
Methysergide—Nausea—Alitretinoin—hematologic cancer	0.00021	0.000276	CcSEcCtD
Methysergide—Convulsion—Prednisone—hematologic cancer	0.00021	0.000276	CcSEcCtD
Methysergide—Rash—Mitoxantrone—hematologic cancer	0.000209	0.000275	CcSEcCtD
Methysergide—Rash—Irinotecan—hematologic cancer	0.000209	0.000275	CcSEcCtD
Methysergide—Dermatitis—Irinotecan—hematologic cancer	0.000209	0.000275	CcSEcCtD
Methysergide—Dermatitis—Mitoxantrone—hematologic cancer	0.000209	0.000275	CcSEcCtD
Methysergide—Nausea—Ifosfamide—hematologic cancer	0.000208	0.000273	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000207	0.000272	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000207	0.000272	CcSEcCtD
Methysergide—Arthralgia—Prednisone—hematologic cancer	0.000206	0.000271	CcSEcCtD
Methysergide—Myalgia—Prednisone—hematologic cancer	0.000206	0.000271	CcSEcCtD
Methysergide—Feeling abnormal—Triamcinolone—hematologic cancer	0.000206	0.000271	CcSEcCtD
Methysergide—Diarrhoea—Cisplatin—hematologic cancer	0.000206	0.000271	CcSEcCtD
Methysergide—Alopecia—Methotrexate—hematologic cancer	0.000206	0.00027	CcSEcCtD
Methysergide—Vomiting—Gemcitabine—hematologic cancer	0.000205	0.00027	CcSEcCtD
Methysergide—Insomnia—Dexamethasone—hematologic cancer	0.000205	0.00027	CcSEcCtD
Methysergide—Insomnia—Betamethasone—hematologic cancer	0.000205	0.00027	CcSEcCtD
Methysergide—Paraesthesia—Dexamethasone—hematologic cancer	0.000204	0.000268	CcSEcCtD
Methysergide—Paraesthesia—Betamethasone—hematologic cancer	0.000204	0.000268	CcSEcCtD
Methysergide—Discomfort—Prednisone—hematologic cancer	0.000204	0.000268	CcSEcCtD
Methysergide—Rash—Gemcitabine—hematologic cancer	0.000204	0.000268	CcSEcCtD
Methysergide—Dermatitis—Gemcitabine—hematologic cancer	0.000204	0.000268	CcSEcCtD
Methysergide—Nausea—Vincristine—hematologic cancer	0.000202	0.000266	CcSEcCtD
Methysergide—Flushing—Epirubicin—hematologic cancer	0.000202	0.000266	CcSEcCtD
Methysergide—Dyspepsia—Betamethasone—hematologic cancer	0.0002	0.000263	CcSEcCtD
Methysergide—Dyspepsia—Dexamethasone—hematologic cancer	0.0002	0.000263	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—hematologic cancer	0.000198	0.000261	CcSEcCtD
Methysergide—Asthenia—Etoposide—hematologic cancer	0.000198	0.00026	CcSEcCtD
Methysergide—Body temperature increased—Triamcinolone—hematologic cancer	0.000198	0.00026	CcSEcCtD
Methysergide—Oedema—Prednisone—hematologic cancer	0.000198	0.00026	CcSEcCtD
Methysergide—Nausea—Mitoxantrone—hematologic cancer	0.000197	0.000259	CcSEcCtD
Methysergide—Nausea—Irinotecan—hematologic cancer	0.000197	0.000259	CcSEcCtD
Methysergide—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000196	0.000258	CcSEcCtD
Methysergide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000196	0.000258	CcSEcCtD
Methysergide—Back pain—Methotrexate—hematologic cancer	0.000196	0.000258	CcSEcCtD
Methysergide—Fatigue—Betamethasone—hematologic cancer	0.000196	0.000257	CcSEcCtD
Methysergide—Fatigue—Dexamethasone—hematologic cancer	0.000196	0.000257	CcSEcCtD
Methysergide—Pain—Betamethasone—hematologic cancer	0.000194	0.000255	CcSEcCtD
Methysergide—Pain—Dexamethasone—hematologic cancer	0.000194	0.000255	CcSEcCtD
Methysergide—Tachycardia—Prednisone—hematologic cancer	0.000193	0.000254	CcSEcCtD
Methysergide—Alopecia—Epirubicin—hematologic cancer	0.000192	0.000253	CcSEcCtD
Methysergide—Nausea—Gemcitabine—hematologic cancer	0.000192	0.000252	CcSEcCtD
Methysergide—Vomiting—Cisplatin—hematologic cancer	0.000192	0.000252	CcSEcCtD
Methysergide—Rash—Cisplatin—hematologic cancer	0.00019	0.00025	CcSEcCtD
Methysergide—Dermatitis—Cisplatin—hematologic cancer	0.00019	0.000249	CcSEcCtD
Methysergide—Diarrhoea—Etoposide—hematologic cancer	0.000189	0.000248	CcSEcCtD
Methysergide—Ill-defined disorder—Methotrexate—hematologic cancer	0.000188	0.000247	CcSEcCtD
Methysergide—Feeling abnormal—Dexamethasone—hematologic cancer	0.000187	0.000246	CcSEcCtD
Methysergide—Feeling abnormal—Betamethasone—hematologic cancer	0.000187	0.000246	CcSEcCtD
Methysergide—Flushing—Doxorubicin—hematologic cancer	0.000187	0.000246	CcSEcCtD
Methysergide—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000186	0.000244	CcSEcCtD
Methysergide—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000186	0.000244	CcSEcCtD
Methysergide—Back pain—Epirubicin—hematologic cancer	0.000183	0.000241	CcSEcCtD
Methysergide—Malaise—Methotrexate—hematologic cancer	0.000183	0.00024	CcSEcCtD
Methysergide—Dizziness—Etoposide—hematologic cancer	0.000182	0.00024	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.00018	0.000237	CcSEcCtD
Methysergide—Dizziness—Prednisolone—hematologic cancer	0.00018	0.000237	CcSEcCtD
Methysergide—Asthenia—Triamcinolone—hematologic cancer	0.00018	0.000236	CcSEcCtD
Methysergide—Body temperature increased—Dexamethasone—hematologic cancer	0.00018	0.000236	CcSEcCtD
Methysergide—Abdominal pain—Betamethasone—hematologic cancer	0.00018	0.000236	CcSEcCtD
Methysergide—Abdominal pain—Dexamethasone—hematologic cancer	0.00018	0.000236	CcSEcCtD
Methysergide—Body temperature increased—Betamethasone—hematologic cancer	0.00018	0.000236	CcSEcCtD
Methysergide—Nausea—Cisplatin—hematologic cancer	0.000179	0.000235	CcSEcCtD
Methysergide—Insomnia—Prednisone—hematologic cancer	0.000179	0.000235	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—hematologic cancer	0.000178	0.000234	CcSEcCtD
Methysergide—Paraesthesia—Prednisone—hematologic cancer	0.000178	0.000233	CcSEcCtD
Methysergide—Ill-defined disorder—Epirubicin—hematologic cancer	0.000176	0.000231	CcSEcCtD
Methysergide—Convulsion—Methotrexate—hematologic cancer	0.000175	0.000231	CcSEcCtD
Methysergide—Vomiting—Etoposide—hematologic cancer	0.000175	0.000231	CcSEcCtD
Methysergide—Dyspepsia—Prednisone—hematologic cancer	0.000174	0.000229	CcSEcCtD
Methysergide—Rash—Etoposide—hematologic cancer	0.000174	0.000229	CcSEcCtD
Methysergide—Dermatitis—Etoposide—hematologic cancer	0.000174	0.000228	CcSEcCtD
Methysergide—Arthralgia—Methotrexate—hematologic cancer	0.000172	0.000227	CcSEcCtD
Methysergide—Chest pain—Methotrexate—hematologic cancer	0.000172	0.000227	CcSEcCtD
Methysergide—Myalgia—Methotrexate—hematologic cancer	0.000172	0.000227	CcSEcCtD
Methysergide—Rash—Prednisolone—hematologic cancer	0.000172	0.000226	CcSEcCtD
Methysergide—Dermatitis—Prednisolone—hematologic cancer	0.000171	0.000225	CcSEcCtD
Methysergide—Malaise—Epirubicin—hematologic cancer	0.000171	0.000225	CcSEcCtD
Methysergide—Fatigue—Prednisone—hematologic cancer	0.000171	0.000224	CcSEcCtD
Methysergide—Discomfort—Methotrexate—hematologic cancer	0.00017	0.000224	CcSEcCtD
Methysergide—Back pain—Doxorubicin—hematologic cancer	0.00017	0.000223	CcSEcCtD
Methysergide—Constipation—Prednisone—hematologic cancer	0.000169	0.000222	CcSEcCtD
Methysergide—Dizziness—Triamcinolone—hematologic cancer	0.000166	0.000218	CcSEcCtD
Methysergide—Convulsion—Epirubicin—hematologic cancer	0.000164	0.000216	CcSEcCtD
Methysergide—Nausea—Etoposide—hematologic cancer	0.000164	0.000215	CcSEcCtD
Methysergide—Feeling abnormal—Prednisone—hematologic cancer	0.000163	0.000214	CcSEcCtD
Methysergide—Asthenia—Dexamethasone—hematologic cancer	0.000163	0.000214	CcSEcCtD
Methysergide—Asthenia—Betamethasone—hematologic cancer	0.000163	0.000214	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—hematologic cancer	0.000163	0.000214	CcSEcCtD
Methysergide—Thrombocytopenia—Methotrexate—hematologic cancer	0.000162	0.000213	CcSEcCtD
Methysergide—Gastrointestinal pain—Prednisone—hematologic cancer	0.000162	0.000213	CcSEcCtD
Methysergide—Nausea—Prednisolone—hematologic cancer	0.000162	0.000213	CcSEcCtD
Methysergide—Arthralgia—Epirubicin—hematologic cancer	0.000161	0.000212	CcSEcCtD
Methysergide—Chest pain—Epirubicin—hematologic cancer	0.000161	0.000212	CcSEcCtD
Methysergide—Myalgia—Epirubicin—hematologic cancer	0.000161	0.000212	CcSEcCtD
Methysergide—Discomfort—Epirubicin—hematologic cancer	0.000159	0.00021	CcSEcCtD
Methysergide—Vomiting—Triamcinolone—hematologic cancer	0.000159	0.000209	CcSEcCtD
Methysergide—Malaise—Doxorubicin—hematologic cancer	0.000158	0.000208	CcSEcCtD
Methysergide—Rash—Triamcinolone—hematologic cancer	0.000158	0.000207	CcSEcCtD
Methysergide—Dermatitis—Triamcinolone—hematologic cancer	0.000158	0.000207	CcSEcCtD
Methysergide—Abdominal pain—Prednisone—hematologic cancer	0.000156	0.000206	CcSEcCtD
Methysergide—Body temperature increased—Prednisone—hematologic cancer	0.000156	0.000206	CcSEcCtD
Methysergide—Diarrhoea—Dexamethasone—hematologic cancer	0.000155	0.000204	CcSEcCtD
Methysergide—Diarrhoea—Betamethasone—hematologic cancer	0.000155	0.000204	CcSEcCtD
Methysergide—Oedema—Epirubicin—hematologic cancer	0.000155	0.000203	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—hematologic cancer	0.000152	0.0002	CcSEcCtD
Methysergide—Thrombocytopenia—Epirubicin—hematologic cancer	0.000151	0.000199	CcSEcCtD
Methysergide—Tachycardia—Epirubicin—hematologic cancer	0.000151	0.000198	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000151	0.000198	CcSEcCtD
Methysergide—Dizziness—Betamethasone—hematologic cancer	0.00015	0.000197	CcSEcCtD
Methysergide—Dizziness—Dexamethasone—hematologic cancer	0.00015	0.000197	CcSEcCtD
Methysergide—Insomnia—Methotrexate—hematologic cancer	0.00015	0.000197	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—hematologic cancer	0.000149	0.000196	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—hematologic cancer	0.000149	0.000196	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—hematologic cancer	0.000149	0.000196	CcSEcCtD
Methysergide—Nausea—Triamcinolone—hematologic cancer	0.000149	0.000195	CcSEcCtD
Methysergide—Paraesthesia—Methotrexate—hematologic cancer	0.000148	0.000195	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—hematologic cancer	0.000148	0.000194	CcSEcCtD
Methysergide—Dyspnoea—Methotrexate—hematologic cancer	0.000147	0.000194	CcSEcCtD
Methysergide—Somnolence—Methotrexate—hematologic cancer	0.000147	0.000193	CcSEcCtD
Methysergide—Dyspepsia—Methotrexate—hematologic cancer	0.000146	0.000191	CcSEcCtD
Methysergide—Vomiting—Betamethasone—hematologic cancer	0.000144	0.00019	CcSEcCtD
Methysergide—Vomiting—Dexamethasone—hematologic cancer	0.000144	0.00019	CcSEcCtD
Methysergide—Rash—Dexamethasone—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Rash—Betamethasone—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Oedema—Doxorubicin—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Dermatitis—Betamethasone—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Dermatitis—Dexamethasone—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000143	0.000188	CcSEcCtD
Methysergide—Fatigue—Methotrexate—hematologic cancer	0.000143	0.000187	CcSEcCtD
Methysergide—Asthenia—Prednisone—hematologic cancer	0.000142	0.000187	CcSEcCtD
Methysergide—Pain—Methotrexate—hematologic cancer	0.000141	0.000186	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	0.000141	0.000185	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—hematologic cancer	0.00014	0.000184	CcSEcCtD
Methysergide—Insomnia—Epirubicin—hematologic cancer	0.00014	0.000184	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—hematologic cancer	0.00014	0.000184	CcSEcCtD
Methysergide—Paraesthesia—Epirubicin—hematologic cancer	0.000139	0.000183	CcSEcCtD
Methysergide—Dyspnoea—Epirubicin—hematologic cancer	0.000138	0.000181	CcSEcCtD
Methysergide—Somnolence—Epirubicin—hematologic cancer	0.000138	0.000181	CcSEcCtD
Methysergide—Feeling abnormal—Methotrexate—hematologic cancer	0.000136	0.000179	CcSEcCtD
Methysergide—Dyspepsia—Epirubicin—hematologic cancer	0.000136	0.000179	CcSEcCtD
Methysergide—Diarrhoea—Prednisone—hematologic cancer	0.000135	0.000178	CcSEcCtD
Methysergide—Gastrointestinal pain—Methotrexate—hematologic cancer	0.000135	0.000178	CcSEcCtD
Methysergide—Nausea—Betamethasone—hematologic cancer	0.000135	0.000177	CcSEcCtD
Methysergide—Nausea—Dexamethasone—hematologic cancer	0.000135	0.000177	CcSEcCtD
Methysergide—Gastrointestinal disorder—Epirubicin—hematologic cancer	0.000134	0.000176	CcSEcCtD
Methysergide—Fatigue—Epirubicin—hematologic cancer	0.000133	0.000175	CcSEcCtD
Methysergide—Pain—Epirubicin—hematologic cancer	0.000132	0.000174	CcSEcCtD
Methysergide—Constipation—Epirubicin—hematologic cancer	0.000132	0.000174	CcSEcCtD
Methysergide—Dizziness—Prednisone—hematologic cancer	0.000131	0.000172	CcSEcCtD
Methysergide—Abdominal pain—Methotrexate—hematologic cancer	0.000131	0.000172	CcSEcCtD
Methysergide—Body temperature increased—Methotrexate—hematologic cancer	0.000131	0.000172	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	0.00013	0.000171	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—hematologic cancer	0.000129	0.00017	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—hematologic cancer	0.000129	0.000169	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—hematologic cancer	0.000128	0.000168	CcSEcCtD
Methysergide—Feeling abnormal—Epirubicin—hematologic cancer	0.000127	0.000168	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—hematologic cancer	0.000127	0.000167	CcSEcCtD
Methysergide—Gastrointestinal pain—Epirubicin—hematologic cancer	0.000126	0.000166	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—hematologic cancer	0.000126	0.000166	CcSEcCtD
Methysergide—Vomiting—Prednisone—hematologic cancer	0.000126	0.000165	CcSEcCtD
Methysergide—Rash—Prednisone—hematologic cancer	0.000125	0.000164	CcSEcCtD
Methysergide—Dermatitis—Prednisone—hematologic cancer	0.000125	0.000164	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	0.000124	0.000162	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—hematologic cancer	0.000123	0.000162	CcSEcCtD
Methysergide—Pain—Doxorubicin—hematologic cancer	0.000122	0.000161	CcSEcCtD
Methysergide—Constipation—Doxorubicin—hematologic cancer	0.000122	0.000161	CcSEcCtD
Methysergide—Abdominal pain—Epirubicin—hematologic cancer	0.000122	0.000161	CcSEcCtD
Methysergide—Body temperature increased—Epirubicin—hematologic cancer	0.000122	0.000161	CcSEcCtD
Methysergide—Asthenia—Methotrexate—hematologic cancer	0.000119	0.000156	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—hematologic cancer	0.000118	0.000155	CcSEcCtD
Methysergide—Nausea—Prednisone—hematologic cancer	0.000117	0.000154	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—hematologic cancer	0.000117	0.000154	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—hematologic cancer	0.000113	0.000149	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—hematologic cancer	0.000113	0.000149	CcSEcCtD
Methysergide—Diarrhoea—Methotrexate—hematologic cancer	0.000113	0.000149	CcSEcCtD
Methysergide—Asthenia—Epirubicin—hematologic cancer	0.000111	0.000146	CcSEcCtD
Methysergide—Dizziness—Methotrexate—hematologic cancer	0.000109	0.000144	CcSEcCtD
Methysergide—Diarrhoea—Epirubicin—hematologic cancer	0.000106	0.000139	CcSEcCtD
Methysergide—Vomiting—Methotrexate—hematologic cancer	0.000105	0.000138	CcSEcCtD
Methysergide—Rash—Methotrexate—hematologic cancer	0.000104	0.000137	CcSEcCtD
Methysergide—Dermatitis—Methotrexate—hematologic cancer	0.000104	0.000137	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—hematologic cancer	0.000103	0.000135	CcSEcCtD
Methysergide—Dizziness—Epirubicin—hematologic cancer	0.000102	0.000134	CcSEcCtD
Methysergide—Vomiting—Epirubicin—hematologic cancer	9.84e-05	0.000129	CcSEcCtD
Methysergide—Nausea—Methotrexate—hematologic cancer	9.82e-05	0.000129	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—hematologic cancer	9.79e-05	0.000129	CcSEcCtD
Methysergide—Rash—Epirubicin—hematologic cancer	9.75e-05	0.000128	CcSEcCtD
Methysergide—Dermatitis—Epirubicin—hematologic cancer	9.74e-05	0.000128	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—hematologic cancer	9.47e-05	0.000124	CcSEcCtD
Methysergide—Nausea—Epirubicin—hematologic cancer	9.19e-05	0.000121	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—hematologic cancer	9.1e-05	0.00012	CcSEcCtD
Methysergide—Rash—Doxorubicin—hematologic cancer	9.02e-05	0.000119	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—hematologic cancer	9.02e-05	0.000119	CcSEcCtD
Methysergide—Nausea—Doxorubicin—hematologic cancer	8.5e-05	0.000112	CcSEcCtD
Methysergide—HTR1A—Signaling Pathways—CCL2—hematologic cancer	1.43e-05	5.97e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6R—hematologic cancer	1.42e-05	5.95e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CREBBP—hematologic cancer	1.42e-05	5.94e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—hematologic cancer	1.42e-05	5.94e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCL2—hematologic cancer	1.42e-05	5.94e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—hematologic cancer	1.42e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—hematologic cancer	1.42e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—JUN—hematologic cancer	1.42e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2—hematologic cancer	1.42e-05	5.92e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—hematologic cancer	1.42e-05	5.92e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6R—hematologic cancer	1.42e-05	5.92e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—JUN—hematologic cancer	1.42e-05	5.92e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	1.41e-05	5.91e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—hematologic cancer	1.41e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—hematologic cancer	1.41e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—JUN—hematologic cancer	1.41e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ESR1—hematologic cancer	1.4e-05	5.86e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—hematologic cancer	1.39e-05	5.81e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FN1—hematologic cancer	1.38e-05	5.79e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	1.38e-05	5.78e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—hematologic cancer	1.38e-05	5.77e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—JUN—hematologic cancer	1.38e-05	5.76e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CDKN1A—hematologic cancer	1.37e-05	5.75e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CDKN1A—hematologic cancer	1.37e-05	5.74e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—hematologic cancer	1.37e-05	5.73e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—hematologic cancer	1.37e-05	5.73e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—hematologic cancer	1.37e-05	5.73e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	1.37e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BAD—hematologic cancer	1.37e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CDKN1A—hematologic cancer	1.36e-05	5.7e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—hematologic cancer	1.36e-05	5.69e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	1.36e-05	5.68e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	1.36e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	1.35e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	1.35e-05	5.64e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	1.35e-05	5.63e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	1.34e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK8—hematologic cancer	1.34e-05	5.61e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	1.34e-05	5.61e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK8—hematologic cancer	1.34e-05	5.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—hematologic cancer	1.34e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—hematologic cancer	1.34e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	1.34e-05	5.58e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.33e-05	5.58e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—hematologic cancer	1.33e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—hematologic cancer	1.33e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK8—hematologic cancer	1.33e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2—hematologic cancer	1.33e-05	5.56e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—hematologic cancer	1.33e-05	5.56e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	1.33e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—hematologic cancer	1.33e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CD80—hematologic cancer	1.33e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KIT—hematologic cancer	1.32e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	1.32e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	1.32e-05	5.54e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—hematologic cancer	1.32e-05	5.53e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	1.32e-05	5.52e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	1.31e-05	5.49e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—hematologic cancer	1.31e-05	5.48e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EP300—hematologic cancer	1.31e-05	5.47e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EP300—hematologic cancer	1.31e-05	5.46e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	1.3e-05	5.45e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	1.3e-05	5.44e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	1.3e-05	5.43e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EP300—hematologic cancer	1.3e-05	5.43e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—hematologic cancer	1.3e-05	5.42e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—JUN—hematologic cancer	1.29e-05	5.41e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FGF2—hematologic cancer	1.29e-05	5.4e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FGF2—hematologic cancer	1.28e-05	5.37e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	1.27e-05	5.32e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SRC—hematologic cancer	1.27e-05	5.32e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EP300—hematologic cancer	1.27e-05	5.31e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SRC—hematologic cancer	1.27e-05	5.31e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	1.27e-05	5.3e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	1.27e-05	5.29e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SRC—hematologic cancer	1.26e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CREB1—hematologic cancer	1.26e-05	5.27e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	1.25e-05	5.25e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—hematologic cancer	1.25e-05	5.24e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—hematologic cancer	1.25e-05	5.23e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—hematologic cancer	1.24e-05	5.2e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—hematologic cancer	1.24e-05	5.18e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—hematologic cancer	1.24e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JAK2—hematologic cancer	1.24e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SRC—hematologic cancer	1.24e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCL2—hematologic cancer	1.23e-05	5.16e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JAK2—hematologic cancer	1.23e-05	5.14e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6R—hematologic cancer	1.23e-05	5.14e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—hematologic cancer	1.23e-05	5.14e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	1.23e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—hematologic cancer	1.23e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—hematologic cancer	1.23e-05	5.13e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—hematologic cancer	1.23e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	1.22e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—hematologic cancer	1.22e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—hematologic cancer	1.22e-05	5.11e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	1.22e-05	5.11e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—hematologic cancer	1.22e-05	5.09e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—hematologic cancer	1.21e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.21e-05	5.07e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—hematologic cancer	1.21e-05	5.05e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	1.21e-05	5.04e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	1.2e-05	5.03e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—hematologic cancer	1.2e-05	5.02e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EP300—hematologic cancer	1.19e-05	4.99e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—hematologic cancer	1.19e-05	4.98e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—hematologic cancer	1.19e-05	4.97e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	1.17e-05	4.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MTOR—hematologic cancer	1.17e-05	4.91e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	1.17e-05	4.9e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK3—hematologic cancer	1.17e-05	4.9e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK3—hematologic cancer	1.17e-05	4.89e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MTOR—hematologic cancer	1.17e-05	4.89e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	1.17e-05	4.89e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	1.16e-05	4.87e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	1.16e-05	4.86e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SRC—hematologic cancer	1.16e-05	4.85e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—hematologic cancer	1.16e-05	4.84e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.15e-05	4.82e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	1.14e-05	4.77e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—hematologic cancer	1.14e-05	4.76e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	1.14e-05	4.76e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—hematologic cancer	1.14e-05	4.76e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFB1—hematologic cancer	1.14e-05	4.75e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFB1—hematologic cancer	1.14e-05	4.75e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—hematologic cancer	1.13e-05	4.73e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	1.13e-05	4.73e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	1.13e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	1.12e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—hematologic cancer	1.12e-05	4.68e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—hematologic cancer	1.12e-05	4.67e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	1.12e-05	4.66e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGF2—hematologic cancer	1.11e-05	4.66e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—hematologic cancer	1.11e-05	4.63e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	1.1e-05	4.62e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	1.1e-05	4.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	1.1e-05	4.6e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	1.1e-05	4.59e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	1.09e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	1.08e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—hematologic cancer	1.08e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2—hematologic cancer	1.08e-05	4.51e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—hematologic cancer	1.07e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—hematologic cancer	1.07e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2—hematologic cancer	1.07e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	1.07e-05	4.47e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JAK2—hematologic cancer	1.07e-05	4.47e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—hematologic cancer	1.07e-05	4.46e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—hematologic cancer	1.05e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—hematologic cancer	1.05e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—hematologic cancer	1.05e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JUN—hematologic cancer	1.05e-05	4.39e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.05e-05	4.38e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—hematologic cancer	1.05e-05	4.37e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—hematologic cancer	1.04e-05	4.37e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JUN—hematologic cancer	1.04e-05	4.37e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—hematologic cancer	1.04e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—hematologic cancer	1.04e-05	4.35e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	1.04e-05	4.34e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—hematologic cancer	1.02e-05	4.28e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	1.02e-05	4.25e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—hematologic cancer	1.02e-05	4.24e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	1.01e-05	4.24e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MTOR—hematologic cancer	1.01e-05	4.24e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	1.01e-05	4.23e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—hematologic cancer	1.01e-05	4.22e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	9.93e-06	4.15e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	9.9e-06	4.14e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	9.88e-06	4.13e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	9.85e-06	4.12e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	9.69e-06	4.05e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EP300—hematologic cancer	9.68e-06	4.05e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	9.67e-06	4.04e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—hematologic cancer	9.66e-06	4.04e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EP300—hematologic cancer	9.63e-06	4.03e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—hematologic cancer	9.61e-06	4.02e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	9.6e-06	4.01e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	9.52e-06	3.98e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	9.42e-06	3.94e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SRC—hematologic cancer	9.41e-06	3.94e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	9.4e-06	3.93e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SRC—hematologic cancer	9.36e-06	3.92e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—hematologic cancer	9.36e-06	3.91e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—hematologic cancer	9.35e-06	3.91e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—hematologic cancer	9.33e-06	3.9e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2—hematologic cancer	9.32e-06	3.9e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—hematologic cancer	9.29e-06	3.88e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—hematologic cancer	9.27e-06	3.88e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	9.17e-06	3.83e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	9.12e-06	3.81e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—hematologic cancer	9.09e-06	3.8e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—hematologic cancer	9.09e-06	3.8e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—hematologic cancer	9.08e-06	3.8e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JUN—hematologic cancer	9.07e-06	3.79e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—hematologic cancer	9.06e-06	3.79e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—hematologic cancer	9.03e-06	3.78e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—hematologic cancer	9.01e-06	3.77e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—hematologic cancer	8.95e-06	3.74e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—hematologic cancer	8.94e-06	3.74e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—hematologic cancer	8.88e-06	3.71e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	8.83e-06	3.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	8.79e-06	3.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—hematologic cancer	8.77e-06	3.67e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—hematologic cancer	8.7e-06	3.64e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	8.67e-06	3.63e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	8.63e-06	3.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	8.58e-06	3.59e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—hematologic cancer	8.57e-06	3.58e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—hematologic cancer	8.56e-06	3.58e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	8.55e-06	3.58e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—hematologic cancer	8.54e-06	3.57e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—hematologic cancer	8.5e-06	3.55e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—hematologic cancer	8.44e-06	3.53e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	8.41e-06	3.52e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—hematologic cancer	8.39e-06	3.51e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	8.37e-06	3.5e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EP300—hematologic cancer	8.36e-06	3.5e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—hematologic cancer	8.32e-06	3.48e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—hematologic cancer	8.17e-06	3.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SRC—hematologic cancer	8.13e-06	3.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	7.92e-06	3.31e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—hematologic cancer	7.9e-06	3.3e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—hematologic cancer	7.89e-06	3.3e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—hematologic cancer	7.84e-06	3.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—hematologic cancer	7.84e-06	3.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—hematologic cancer	7.82e-06	3.27e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—hematologic cancer	7.82e-06	3.27e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—hematologic cancer	7.79e-06	3.26e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—hematologic cancer	7.75e-06	3.24e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—hematologic cancer	7.68e-06	3.21e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	7.49e-06	3.13e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—hematologic cancer	7.29e-06	3.05e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	7.27e-06	3.04e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—hematologic cancer	7.21e-06	3.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	7.16e-06	2.99e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	7.12e-06	2.98e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—hematologic cancer	6.93e-06	2.9e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—hematologic cancer	6.89e-06	2.88e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—hematologic cancer	6.73e-06	2.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—hematologic cancer	6.63e-06	2.77e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—hematologic cancer	6.59e-06	2.76e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—hematologic cancer	6.34e-06	2.65e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—hematologic cancer	6.31e-06	2.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	6.19e-06	2.59e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—hematologic cancer	5.98e-06	2.5e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—hematologic cancer	5.85e-06	2.45e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—hematologic cancer	5.82e-06	2.43e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—hematologic cancer	5.72e-06	2.39e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—hematologic cancer	5.48e-06	2.29e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—hematologic cancer	5.05e-06	2.11e-05	CbGpPWpGaD
